TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00200005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Type: Implantable neurostimulator; InterStim
Description: Treatment with InterStim Therapy: all patients meeting inclusion/exclusion criteria undergo test screening and those who have successful outcomes receive a permanent implant.
Study: NCT01825629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary therapy
Description: Physical Therapy: Cervical traction, Cranium fore flexion 15 °, Open-close mouth dental contactless (10 mm), Opening movement with a small resistor (one finger on chin), Flexion of the head, without actually lifting, resisting in the front, Occipital extension, Cranium fore flexion 15 °, Cervical traction.~Myofascial Therapy: Induction suboccipital, compression - decompression of the temporomandibular joint, horizontal induction of the temporomandibular joint, deep fascia induction in the temporal region, deep induction of the masseter fascia, deep induction of the external pterygoid, and induction of intraoral pterygoid.~Deontology therapy: the patient are going to port a deprogramming occlusal splint every night, an average of 8 hours per day, for 15 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01551732

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT
Description: 10 session manualized cognitive behavioral anger control therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT with RAGE-Control
Description: 10 session manualized cognitive behavioral anger control therapy augmented with interactive biofeedback videogame.
Study: NCT00822133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: lidocaine 5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: ketamine cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: non-active drug cream
Description: will be put on the skin
Study: NCT04392505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab Injection
Description: Included patients will receive durvalumab (fixed dose, 1500mg Q4W) until progressive disease and no clinical benefit, intolerable toxicity or patient's wish, for a maximum duration of 12 months. Treatment with durvalumab should start \<5 weeks after last radiotherapy dosing.
Study: NCT03570684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cable Tie
Description: During the operation, after mobilization the rectum, the disinfected Cable Tie was introduced into the pelvic cavity.then the rectum was bundled by the tie which was easy as the tie is auto-locked. pulling the tie and the rectum would be explored clearly, and then the endoscopic linear cutter was introduced to transect the rectum. the tie made the rectum folded not applanate, that the cutter was able to transect the rectum easily and with less reloader. when the rectum was resected completely, the tie was get out with the specimen, and do not live in the abdomen.
Study: NCT03369548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple
Description: 2 Renetta Canada apples and 2 placebo capsules/ day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oats
Description: 40g jumbo rolled oats with semi-skimmed milk and 2 placebo capsules / day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri NCIMB 30242
Description: 2 probiotic capsules and 40g cornflakes with semi-skimmed milk / day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cornflakes
Description: 40g cornflakes with semi-skimmed milk and 2 placebo capsules/ day.
Study: NCT03531424

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiographic guided PCI
Description: Angiographic guided PCI is coronary revascularization based on stand-alone angiography.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Augmented-Reality CTA guided PCI
Description: Augmented-Reality CTA guided PCI is coronary revascularization based on systematic use of CTA datasets displayed in augmented-reality glass plus coronary angiography.
Study: NCT04080804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: A fully human anti-programmed death 1 (PD-1) monoclonal antibody checkpoint inhibitor, that blocks a signal that prevents activated T cells from attacking the cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: A fully human anti-programmed death 1 (PD-1) monoclonal antibody checkpoint inhibitor, that blocks a signal that prevents activated T cells from attacking the cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: A monoclonal antibody with anti-Lymphocyte-activation gene 3 (LAG-3) (immune checkpoint receptor protein found on the cell surface) activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: A monoclonal anitibody that targets CTLA-4, a protein receptor, that down regulates the immune system.
Study: NCT01816750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac GSI
Description: A novel method of computed tomography scanning (Cardiac Gemstone Spectral Imaging - Cardiac GSI) and image reconstruction (Adaptive Statistical Iterative Reconstruction- ASIR.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac GSI
Description: A novel method of computed tomography scanning (Cardiac Gemstone Spectral Imaging - Cardiac GSI) and image reconstruction (Adaptive Statistical Iterative Reconstruction- ASIR.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac GSI
Description: A novel method of computed tomography scanning (Cardiac Gemstone Spectral Imaging - Cardiac GSI) and image reconstruction (Adaptive Statistical Iterative Reconstruction- ASIR.
Study: NCT01834755

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of psychological phenotype
Study: NCT01180855

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill nightly for 42 nights.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rozerem 8mg
Description: Rozerem 8mg pill, nightly for 42 nights

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rozerem 8mg in combination with Multi Component Behavior Therapy
Description: Rozerem 8mg pill nightly for 42 nights with 4 sessions and 2 telephone calls of Multi Component Behavior Therapy.
Study: NCT00735995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (individual)
Description: The Coping Cat program, 12 weekly sessions, two additional parent meetings

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (group)
Description: The Coping Cat program, 12 weekly sessions, two additional parent meetings
Study: NCT03177668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YS110
Description: Intravenous administration
Study: NCT03364322

Intervention type: OTHER
Intervention: Observation
Description: Observation
Study: NCT01981694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751
Description: Single doses, given by oral solution, starting at 0.25 mg up to a possible maximum of 7.5 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator. One dose will be given in the fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751
Description: It is believed that the maximum tolerated dose of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 5 subjects will be given a placebo as a comparator.
Study: NCT01437826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antioxidants
Description: tablets composed of 200 mcg selenium \[as l-selenomethionine\], 30 mg zinc, 2 mg vitamin A \[retinol\], 180 mg vitamin C \[ascorbic acid\] and 30 mg vitamin E \[D-α-tocopherol acetate\]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo had an identical appearance as intervention
Study: NCT01532115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 50 mg and 800 mg of BIA 9-1067 (single-dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: 400 mg moxifloxacin (single-dose)
Study: NCT00867438

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sigmoidoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Study: NCT02414048

Intervention type: DRUG
Group type: OTHER
Intervention: Pimonidazole
Description: Pimonidazole will be administered orally and will serve to demarcate the hypoxic areas in the tumour
Study: NCT03064516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endocrown
Description: In experimental group, the researches will be performed in the Endocrown group- only the ceramic restoration will fill the pulp chambre in teeth treated endodontically. Cusps will be preserved.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Onlay and fiber pin
Description: In control group, the researches will be performed in the onlay ceramic restorations with glass fiber pin group in endodontically treated teeth- the teeth receive a fiberglass pin in the main root canal and composite resin filling. Cusps will be preserved.
Study: NCT01049113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 013105
Description: 2-hour intravenous infusion once a week. Starting dose is 17 mg. Maximum dose will be 1525 mg.
Study: NCT03341312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study: NCT00575900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: 12 weeks of dietary intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: 12 weeks of dietary intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary intervention
Description: 12 weeks of dietary intervention
Study: NCT01769352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PredA + Kelac
Description: At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawl. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PredA + Kelac
Description: At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawl. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.
Study: NCT00255515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment for schizophrenia
Description: various standard therapies
Study: NCT03411590

Intervention type: OTHER
Group type: OTHER
Intervention: Fortified milk Powder
Description: Toddlers will be allocated to the 200 ml group and will receive on a daily basis 32g of growing up milk powder respectively, in doses of 16 g, which can be reconstituted with 180 ml water to a final volume of about 200 ml of milk. The intervention period will last for 6 months. For the 200 ml test group, this translates into 32 g of growing up milk powder supply as one dose per day (in the morning)

Intervention type: OTHER
Group type: OTHER
Intervention: Fortified milk Powder
Description: Toddlers will be allocated to the 200 ml group and will receive on a daily basis 32g of growing up milk powder respectively, in doses of 16 g, which can be reconstituted with 180 ml water to a final volume of about 200 ml of milk. The intervention period will last for 6 months. For the 200 ml test group, this translates into 32 g of growing up milk powder supply as one dose per day (in the morning)

Intervention type: OTHER
Group type: OTHER
Intervention: Fortified milk Powder
Description: Toddlers will be allocated to the 200 ml group and will receive on a daily basis 32g of growing up milk powder respectively, in doses of 16 g, which can be reconstituted with 180 ml water to a final volume of about 200 ml of milk. The intervention period will last for 6 months. For the 200 ml test group, this translates into 32 g of growing up milk powder supply as one dose per day (in the morning)
Study: NCT02758002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Firm ablation for transitional AF rotors
Description: Transitional AF rotors will be mapped and ablated as part of this study. All subjects will undergo this ablation after standard PVI and Firm ablation for sustained rotors.
Study: NCT00952484

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: asfotase alfa
Description: 2 mg/kg subcutaneous injection three times per week for 6 months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: asfotase alfa
Description: 3 mg/kg subcutaneous injection three times per week for 6 months.
Study: NCT06113796

Intervention type: OTHER
Intervention: Surgery
Description: Robotic rectal resection, either sphincter preserving or extirpation

Intervention type: OTHER
Intervention: Surgery
Description: Robotic rectal resection, either sphincter preserving or extirpation
Study: NCT01156571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cangrelor P2Y12 (platelet) inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel - 300 or 600 mg (study arm)
Description: Over encapsulated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg post cangrelor
Description: over-encapsulated clopidogrel (600 mg)
Study: NCT03008967

Intervention type: OTHER
Intervention: Arthroplasty and postoperative rehabilitation.
Description: Patients undergoing total knee or total hip arthroplasty and their response to postoperative rehabilitation.
Study: NCT03768479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FES-PET
Description: 18F-FES-PET/CT imaging before and after cycle 1 treatment with the first line Fulvestrant
Study: NCT03355417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OT-SI
Description: Occupational therapy using a sensory integration approach (OT-SI) 3x per week for 10 weeks. A typical session will be 1 hour (total of 3 hours per week).
Study: NCT02822222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium citrate, tribasic anhydrous soft gelatin capsule
Description: 110 mg elemental magnesium/capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo soft gelatin capsule
Description: 0 mg elemental magnesium/capsule
Study: NCT06449040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal amphotericin B (AmBisome®)
Description: Liposomal amphotericin B (AmBisome®) - intravenous use, twice a week until total dose is achieved

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal amphotericin B (AmBisome®)
Description: Liposomal amphotericin B (AmBisome®) - intravenous use, twice a week until total dose is achieved

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal amphotericin B (AmBisome®)
Description: Liposomal amphotericin B (AmBisome®) - intravenous use, twice a week until total dose is achieved
Study: NCT00643916

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)
Description: 0.5 mL, Intramuscular (at age 9 and 12 months)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)
Description: 0.5 mL, Intramuscular (at age 9 and 15 months)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)
Description: 0.5 mL, Intramuscular (at age 12 and 15 months)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)
Description: 0.5 mL, Intramuscular (at age 15 months)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)
Description: 0.5 mL, Intramuscular (at age 18 months)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
Description: 0.5 mL, Subcutaneous (at 3 years to \<6 years of age)
Study: NCT05279781

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non surgical root canal treatment
Description: Complete root canal treatment will be performed followed by direct restoration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy
Description: Full pulpotomy followed by direct restoration
Study: NCT02101229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin, Asp(B28)-
Description: the insulin dose is calculated by the Diabeloop algorithm and then administered to the patient
Study: NCT01494337

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HOLEP
Description: USING HOLMIUM LASER, the prostate adenoma will be enucleated and removed into small pieces

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVEP-XPS
Description: Greenlight laser will be used with high power setting for selective vaporization of the prostate adenoma, using 180 watt XPS laser machine
Study: NCT01785680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Protocol
Description: Implement an integrated protocol in Sierra Leone for the management of MAM and non-complicated SAM that uses a single anthropometric indicator as well as the same food but in different doses to treat the continuum of malnutrition. MAM children will be given 75 g/kg/day of RUTF whereas SAM will be given 175 gr/kg/day of RUTF until MUAC\>12.5 cm is reached. Then child will be given LNS, a bed net, albendazole, zinc, referral for immunizations compliant with current WHO recommendations, oral rehydration salts to give if the child has more than three loose watery stools in 24 hours, and asked to return for follow-up in 1, 3 and 6 months. Caretakers will be instructed to seek medical care sooner if the child has fever, poor appetite or signs of an acute illness.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current protocol
Description: Current protocol for treating MAM in emergencies is supplemental food distribution, often providing a fortified blended food (FBF) that requires cooking. This treatment is the standard today for treating children with MAM.
Study: NCT01799564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micropulse
Description: Between 1 and 3 sessions of micropulse laser will be applied in the inferior hemiretina of the randomly selected eye
Study: NCT04796441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-γδT
Description: Biological: CAR-γδT; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
Study: NCT01315093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin, Low-Molecular-Weight
Description: Heparin from start till hcg test

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: no heparin
Study: NCT03982602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Subjects will be provided with the Ketogenic diet in the form of tube feeds once the decision is made to start the patient on diet.
Study: NCT03544346

Intervention type: OTHER
Intervention: Exploratory brain and general health assessment
Description: Exploratory brain and general health assessment

Intervention type: OTHER
Intervention: Exploratory brain and general health assessment
Description: Exploratory brain and general health assessment
Study: NCT03393000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate plus SOC
Description: Trans Sodium Crocetinate (TSC) plus the Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
Study: NCT02686580

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagen paste
Description: Permacol cross-linked collagen paste, 2.5-3.5 mls to be injected into the MRI defined fistula tracts 7-10 days following drainage of the anorectal abscess.
Study: NCT02265302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 wetability improved formulation (WIF) tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01313702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polipillV1
Description: polipill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polipillV2
Description: Polipill version 2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: the drugs used in clinical practice, defined by physician
Study: NCT03331718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PGA felt reinforcement
Description: During pancreaticojejunostomy, 1) a 0.3 mm thick PGA felt (Neoveil®, Gunze, Japan) is pasted on the ventral side and the dorsal side of pancreatic parenchyma, through which suture between pancreatic parenchyma and jejunum is performed. 2) Before abdominal closure (after completion of all reconstruction, after washing in the abdominal cavity), a 0.15 mm thick PGA felt is further covered around the anastomotic site and fibrin glue is sprayed.